Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective increased by Canaccord Genuity Group from $64.00 to $98.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also weighed in on the stock. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday. The Goldman Sachs Group raised their target price on Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Finally, Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and an average target price of $87.38.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $74.34 on Wednesday. The business’s 50 day moving average price is $59.04 and its 200-day moving average price is $51.13. Kiniksa Pharmaceuticals International has a 1 year low of $29.90 and a 1 year high of $82.94. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.30. The company had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International will post 1.38 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 51.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. EverSource Wealth Advisors LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the period. Osaic Holdings Inc. acquired a new position in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. KBC Group NV acquired a new position in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $34,000. Smartleaf Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.